

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RE APPLICANT

: Jackowski et al.

INVENTION

: Biopolymer Marker Indicative Of Disease State Having A Molecular

Weight Of 1350 Daltons

SERIAL NUMBER

: 09/845,729

FILING DATE

: April 30, 2001

EXAMINER

:Nguyen, Bao Thuy.

GROUP ART UNIT

: 1641

OUR FILE NO.

: 2132.031

CERTIFICATE UNDER 37 CFR 1.8(a)
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Commissioner for Patents
P.O. Box 1450 Augustandria, VA 22313-1450 on

Mail Stop: Fee Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

DECLARATION UNDER 37 CFR § 1.132

- I, George Jackowski, do hereby declare as follows:
- 1. I am one of the named inventors of the application entitled "Biopolymer Marker Indicative of Disease State Having A Molecular Weight of 1350 Daltons", having U.S. Application Serial No. 09/845,729, filed April 30, 2001.
- 2. In the Office Action mailed on May 04, 2004, claims 36-40, (as originally presented) were rejected under 35 U.S.C. 112, first paragraph because the claimed invention allegedly contains subject matter which was not described in the specification in such a way McHale & Slavin P.A. 2132.032 -Declaration 37 CFR 1.132 Page 1 of 3

as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The claims (as currently amended) have been limited to an isolated biopolymer marker having SEQ ID NO:1 (the 1350 dalton marker) useful in methods for determining the presence of the biopolymer marker. The method of the invention as recited in claim 36 involves confirming the presence of the isolated biopolymer marker having SEQ ID NO:1 in the patient sample wherein the presence of the biopolymer marker is indicative of a link to myocardial infarction or renal failure.

- 3. The data provided in attached Appendix A was originally filed in Applicant's application no. 09/846,330, now Pub. No. U.S. 2002/016042C, both applications were filed on April 30, 2001. The data further clarifies the identification of SEQ ID NO: 1 in serum samples of patients being evidentiary of a renal failure or myocardial infarction sampled from patients suffering from a variety of disease states, see pages A3 to A4 of Appendix A.
- 4. This declaration (including the attached Appendix A) is provided in order to show data obtained from a clinical trial involving over 500 patients suffering from a variety of disease states, see page 32 lines 9 to 15 of Pub. No. U.S. 2002/0160420. The patient specific samples and data are used to formulate a library of proteomic materials having characteristics identifiable with both normal and abnormal physiological conditions or predictive hallmarks thereof. The data on pages A3 to A4 of Appendix A indicates the patients from which the isolated McHale & Slavin P.A. 2132.032 -Declaration 37 CFR 1.132 Page 2 of 3

biopolymer marker consisting of SEQ ID NO:1 (the 1350 dalton marker) was confirmed are linked to myocardial infarction or renal failure. This Appendix A does not represent results obtained from additional experimentation. This data was obtained in the original experiments performed at the time of the invention.

The undersigned declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the Application or any patent issuing thereon.

Nov 4 2004

Date

George Jackowski

\\Ns2\client files\2100-2199\2132 -Syn-X\2132_000031 - Marker 1350\Amendments\2132_031.132.wpd

McHale & Slavin P.A. 2132.032 -Declaration 37 CFR 1.132 Page 3 of 3

	aniianhan	(G)DFLAEGGGVR(G)	(G)OF LAEGGGVA(G)	(a) Paragava(a)	(E)GOTLAEGGGVR(G)	(E)GDFLAEGGGVR(G)	(E)GDFLAEGGGVR(G)	(E)GDFLAEGGGVR(G)	(E)GDFLAEGGGVR(G)	(D)PEVRPTSAVAA(-)	(D)PEVRPTSAVAA(-)	(D)PEVRPTSAVAA(-)	(D)PEVRPTSAVAA(-)	(D)PEVRPTSAVAA(-)	(D)PEVRPTSAVAA(-)	(G)EGDFLAEGGGVR(G)	(G)EGDFLAEGGGVR(G)	(G)EGDFLAEGGGVR(G)	(G)EGDFLAEGGGVR(G)	(q)EGDFLAEGGGVR(G)	(G)EGDFLAEGGGVR(G)	(G)EGDFLAEGGGVR(G)	(G)EGDFLAEGGGVR(G)	(G)EGDFLAEGGGVR(G)	(G)EGDFLAEGGGVR(G)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)
Protein Name	Alpha Fibringen	Alpha Fibrinogen	Alpha Fibrinogen	Aloha Fibrinogen	Aloha Fibring	Alpha Fibringen	Alpha Fibringen	Applied Fibrilloger	Aprila Fibrinogen	Apolipoprotein	Apolipoprotein	Apolipoprotein	Apolipoprotein	Apolipoprotein	Apolipoprotein	Alpha Fibrinogen	Aipha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f				
MΜ	1020	1020	1020	1077	1077	1077	1077	1077	1004	/80	/601	1097	1097	/601	/801	007	1200	1206	1206	1206	1206	1206	1206	1206	1206	1211	1211	1211	1211	177	1777	1211	177	1211	1211	1211	1211	1211	1211	1211	1717	1211
Disease	W	W	M	IM	Σ	W	Ĭ.	IW	Tyne II Dishetee	Type II Dishotes	Type II Diabetes	Type II Diabetes	Type II Diabates	Type II Diabetes	Popul Eathur	Donal Callule	מושו בשותופ	Renal Fallure	Kenal Failure	Renai Failure	Kenal Fallure	Renal Failure	Renal failure	Renal failure	Kenal failure	W	E .	N.	Z Z	IM.	MI	IN IN	MI	IMI	IM I	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke ICH	1	7
	MI, Hx of arthritis,			. 61	W	Acute MI, SK???	Non-Q wave MI, Hx HTN		Rectal bleed, Asthma, NIDDM	MOGIN	A.fib. Diabetes smoker HTN		A.fib. Diabetes smoker HTN						•			in the second of	Unstable angina, nemodialysis	Basid attal Eth Delay III. Con I	Serie and Tio, Tiol ax CAN nemodialysis	GE (Isoschaosophae) 35)	Inferior MI Histal Homis	MI NIDOM							Acute CVA Basal gardin	HTN previous CVA CVA CARON	CVA transforts VA	TO NATH	Prior CVA acute CVA (1 MCA)	HTN. acute CVA (R subcortical	Diabetes, acute CVA (R pari	/months of the same for the sam
	65	-	ļ)	28	52	92		29	77	62	73	62		82	67	77	8	65	20	65	99	3 8	8	77	. 65	200	65	28	52	65				54	72	47	56	72	72	29	
Gender	Σ		ı	4			Σ		ц.	ட	Σ	Σ	Σ		Σ	L	u	Σ	Σ	L	L	. 2	Σ	u	Ŀ	. ≥	ш	ட	Σ	Σ	Σ				u.	Σ	≥	Σ	Σ	Σ	L.	
Code #	SO CON 07	HNS-8328	2500-0NIC	90 NOO 76	ST CON 14	SJ CON 19	SJ CON 21	HNS-SJ28	SJ CON 05	SJ CON 06	TWH-039	184-988	TWH-039	184-988	SJ CON 01	SJ CON 05	SJ CON 06	SJ CON 09	SJ CON 07	SJ CON 10	SJ CON 14	SJ CON 04	SJ CON 11	SJ CON 13	SJ CON 06	SJ CON 07	SJ CON 10	SJ CON 14	SJ CON 17	SJ CON 19	SJ CON 21	HNS-SJ22	HNS-SJ28	HNS-SJ33	CU-15	CU-18	CU-19	CU-30	CU-33	CU-37	CU-38	

Socionos	ימייוסאסביאוחמיה/	(H)DINMESASIL(K)	(H)BIHMESASI (D)	(H)RIHWESASI (B)	(H)DIDIVIERACI (A)	(H)NITWESASEL(N)	(H)DIDIVIERASI (A)	(H)NINNESASEL(R)	(T)RIDWESASLL(R)	(A)RIMWEGASLL(R)	(H)KIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	ЭI.	(H)KIHWESASLL(R)	(H)KIHWESASLL(R)	(H)KIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)		(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)
Protein Name	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement Caf	Complement C3f	Complement Cat	Complement Col	Complement Cat	Complement Car	Complement Car	Complement Cal	Complement	Complement Ost	Complement Col	Complement C3r	Complement C3f	Complement C3t	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f
. MM	1211	1211	1211	1211	1211	1211	1211	1211	1211	1011	1211	1244	1211	1211	1211	1211	10,	177	177	1171	1211	1771	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348
Disease	CFF	분	托	SH.	분	CHF	분	붕	SF	#5°	분	E E		HZ.	H.	H	150 140 140 140 140 140 140 140 140 140 14	2 2		בוב	7 2 6	E)	M	M	MI	Ψ.	⊠	W	Σ.	Z.	M	E	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH
Patient History	STAGE 3	STAGE 3	STAGE 3	STAGE 4	STAGE 3	STAGE 3	STAGE3 - DEAD	STAGE 3	STAGE 3	STAGE 3	STAGE 3	Acute MI - STAGE 3		STAGE 4	STAGE 3	STAGE 3	STAGE 3				STAGES			Homodishie	rieiilodialysis homodialisisis	Hernodialysis						W/W ct/schacos HOI	IOII, secondary to Avivi	Active CVA Boselia	LTN IOU SELECTION	TIN, ICH right thaimic	HIN, previous CVA, CVA (R MCA) used tPA	CVA, transfer to VA	HTN, ICH	LTN COM, SCUTE CVA (L MCA)	HIN, acute CVA (R subcortical	nin, Diabetes, acute CVA (K panetal)
er Age	61	65	9	75	77	65	29	29	79	09	43	45	29	99	51	49	29	76	51	63	2	77	95	3 6	3 8	3 8	3 2	26	3			90	3 4	7.7	3	3 5	7,	ţ (9 5	7,2	7,	5
Gender	Σ	щ	L.	щ	4	ıL	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Ц.	Σ	Σ	Σ	ш	Σ	Σ	2	L	2	<u> </u>	. u	- ≥	Σ	2	2			L	. 4	. և	. 2	2	2	2	2	2	<u> E</u>	
Code #	23604 - KKB	23707 - KL	22703 - MMS	20206 - MM	22103 - GM	21813 - GR	23008 - GFB	23402 - HM	20208 - HIF	22803 - HB	23616 - JGK	20803 - EW	23421 - FB	22813 - CL	23130 - ER	23105 - FC	23116 - FC	20414 - EYG	23130 - ER	23134 - FC	20102 - EAB	SJ CON 06	SJ CON 07	SJ CON 10	S.I CON 14	S.I CON 17	00 00 N	S. CON 21	HNS-S.122	HNS-S.128	HNS-S.133	CU-69	CU-12	CU-15	C11-10	21-18	170	6 - 00	0030	CO-33	86-130	1

Γ			T	T	1	Ţ					Ţ																					Γ	Γ			Τ	T	T	T	T	T	T
a Duai IDAS	eorienteo (d) 13 v OB/Vinight L	(T)HRIHWESASLL(K)	(T)HRIHWESASI (P)	(T)HRIHWESASI (B)	(T)HBIHWESASI (D)	(T) I I I I I I I I I I I I I I I I I I I	(T)UDIUMESASEL(R)	(T) THIN ESPORT (K)	(1)HKIHWESASLL(R)	(I)HKIHWESASLL(R)	(1)HKIHWESASLL(R)	(1)HKIHWESASLL(R)	(T) HRIHWESASLL(R)	(I)HKIHWESASLL(R)	(T)HKIHWESASLL(R)	(T)HKIHWESASLL(R)	(1)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(D)SESDFLAEGGGVR(G)	(D)SESDFLAFGGGVR(G)	(D)SESDFLAEGGGVR(G)	(D)SESDFLAEGGGVR(G)	(D)SESDFLAEGGGVR(G)																			
Protein Name	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement Cat	Complement Co.	Complement Col	Complement C3f	Complement Col	Complement Cat	Complement Cal	Complement Cat	Complement Cat	Complement Co.	Colinplement Car	Complement C31	Complement C31	Complement C3r	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Alpha Fibrinogen																
MM	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	13/18	4240	1340	1340	040	1348	340	1348	1348	1350	1350	1350	1350	1350	1350	1350	1350	1350	1350	1350	1350	1350	1350	1350	1350	1350
Disease	Stroke-ICH	Stroke-ICH	Stroke-ICH	당	뚱	붕	분	FS	F	H.	CHF	AH.O	CHF	H20	CAF	CHF	HH.	100		100		בון בון	ב	5	ב ב	Renal Fallure	Kenal Fallure	IM C	Renal rallure	Reigi Fallure	IIM	Reliai railure	ž	Renal Failure	W	Kenal Failure	Σ	W	M	Ξ	W	Ψ
Patient History	HTN, Prior CVA, ICH (R thalamic hemorrhage)	ا ر ا	HTN, Prior CVA, ICH	STAGE 3	STAGE 3	STAGE 3	STAGE 4	STAGE 3	STAGE 3	STAGE3 - DEAD	STAGE 3	STAGE 3	STAGE 3	STAGE 3	Acute MI - STAGE 3	STAGE 3	STAGE 4	STAGE 3		STAGE 3																						
1 7 1	64	€	43	61	65	29	75	77	92	29	29	62	9	43	45	59	99	51	64	59	9/	51	62	02	82	67	12	77	80	65	65	50	200	S S	85	200	200	70	8	+	+	1
Gender	Σ	∑ :	Σ.	ا ح	_	u	ட	ட	L	Σ	Σ	Σ	Σ	Σ	Σ	Σ	L	Σ	Σ	Σ	L	Σ	Σ	Σ	Σ	u	<u>u</u>	LL	Σ	Σ	Σ	L	L	L	. u	. 2	Ť	†	2	†	+	1
П	09-DO	99-02	6/-00	23504 - KKB	23/0/ - KL	22/03 - MMS	20206 - MM	22103 - GM	21813 - GR	23008 - GFB	23402 - HM	20208 - HIF	22803 - HB	23616 - JGK	20803 - EW	23421 - FB	22813 - CL	23130 - ER	23105 - FC	23116 - FC	20414 - EYG	23130 - ER	23134 - FC	20102 - EAB	SJ CON 01	SJ CON 05	SJ CON 06	SJ CON 06:	STCON-09	SJ CON 07	SJ CON 07	SJ CON 10	SJ CON 10	S.I CON 14	SJ CON 14	S.I CON 17	S.I. CON 19	S. I CON 21	HNS-0-122	HNS-5322	HNS-S.133	2222

Code #	Gender	Age	Patient History	Disease	MΜ	Protein Name	Sequence
SJ CON 04	Σ	99	Unstable angina, hemodialysis	Renal failure	1350	Alpha Fibrinogen	(D)SESDEL AEGGGVR(G)
SJ CON 11	Σ	8	Unstable angina, hemosdialysis	Renal failure	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SU CON 13	-	8	Rapid atrial Fib, Prior Hx CAN hemodialysis	Renal failure	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
20803 - EW	Σ	42	Acute MI - STAGE 3	CHF	1406	Serum Albumin	(R)DAHKSEVAHRFK(D)
23421 - FB	Σ	23	STAGE 3	당	1406	Serum Albumin	(R)DAHKSEVAHREK(D)
22813 - CL	L	8	STAGE 4	유	1406	Serum Albumin	(R)DAHKSEVAHREK(D)
23130 - ER	Σ	21	STAGE 3	땅	1406	Serum Albumin	(R)DAHKSEVAHREK(D)
23105 - FC	Σ	8	STAGE 3	분	1406	Serum Albumin	(R)DAHKSEVAHREK(D)
23116 - FC	≥	29	STAGE 3	SH	1406	Serum Albumin	(R)DAHKSEVAHREK(D)
20414 - EYG	щ	92	STAGE 3	분	1406	Serum Albumin	(R)DAHKSEVAHREK(D)
23130 - ER	Σ	21	STAGE 3	出	1406	Serum Albumin	(R)DAHKSEVAHREK(D)
23134 - FC	Σ	62		CH.	1406	Serum Albumin	(R)DAHKSEVAHREK(D)
20102 - EAB	Σļι	2	STAGE 3	CHF	1406	Serum Albumin	(R)DAHKSEVAHRFK(D)
SO CON GO	_	1		Mi	1449	Complement C3f	(I)THRIHWESASLL(R)
SON OV	∑ և	ဂ္ဂ		Z	1449	Complement C3f	(I)THRIHWESASLL(R)
S CON 10	_	3		M	1449	Complement C3f	(I)THRIHWESASLL(R)
92 CON 14	L :	ဌ		Σ	1449	Complement C3f	(I)THRIHWESASLL(R)
ST NOO TO	Σ :	28		W	1449	Complement C3f	(I)THRIHWESASI I (R)
ST NOO TO	Σ	52		M	1449	Complement C3f	(I)THRIHWESASI I (R)
52 CON 21	Σ	65		M	1449	Complement C3f	(I)THRIHWESASLL(R)
2779-SNH				Σ	1449	Complement C3f	(I)THRIHWESASI I (R)
HNS-8028				Ξ	1449	Complement C3f	(I)THRIHWESASLL(R)
2502-2NIL	l	8		W	1449	Complement C3f	(I)THRIHWESASLL(R)
CO-68		<u> </u>	ICH, secondary to AVM	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
20-12	L L	4 2	HO	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
200	١	5	Acute CVA, Basal ganglia	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
21-10	Σ	8 8	HIN, ICH right thalmic	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
20-14	≅ u	3		Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
20-10	_ 2	9 5	HIN, ICH (cerebellar vermis)	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
100	2	7 (H I N, previous CVA, CVA (R MCA) used tPA	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
80-10	2	1 1	CVA, transfer to VA	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
01-30	2	CC	ביסי אויי	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
2000	2	8	HIN, ICH	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
00-33	≥ ≥	7 52	Prior CVA, acute CVA (L MCA)	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
200	ΣL	7 [TIN, acute CVA (R subcortical	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
85-00	- 2	ò	HTN, Diabetes, acute CVA (R parietal)	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
00-00	Σ :	\$ 3	ICH (R thalar	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
20-00	≥ 2	64		Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
23604 770	≥ ≥	3 5	HIN, PHOFICA, ICH	Stroke-ICH	1449	Complement C3f	(I)THRIHWESASLL(R)
2377 - KI	∑u	0 4	STAGE 3	문	1449	Complement C3f	(I)THRIHWESASLL(R)
		3	S JAGE 3	늄	1449	Complement C3f	(I)THRIHWESASLL(R)

OGGOTION		(I) HKIHWESASLL(R)	(I) I HKIHWESASLL(K)	(I) THINKEOACL(K)	(I) I I I I I I I I I I I I I I I I I I	(I) I HRIHWESASIL(R)	(I) THE THINK BY SELLING	(I) I TRIMWESASLL(R)	(I) I HRIHWESASLL(R)	(I) I HKIHWESASLL(R)	(I) I HRIHWESASLL(R)	(I) I HRIHWESASLL(R)	(I) I HKIHWESASLL(R)	(I)IHRIHWESASLL(R)	(I) I HRIHWESASLL(R)	(I) I HRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(A)DS&EGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(T)ADSGEGDFLAEGGGVR(G)	(T)ADSGEGDFLAEGGGVR(G)	(T)ADSGEGDFI AFGGGVR(G)	(R)DAHKSEVAHREKD(I)	(R)DAHKSEVAHBEKD(I)	(R)DAHKSEVAHREKO(I)	(R)DAHKSEVAHRFKD(L)
Protein Name	Complement Cat	Complement Cat	Complement C3f	Complement C3f	Complement Caf	Complement C3f	Complement C3f	Complement	Complement Cat	Complement	Complement Car	Complement Car	Complement Col	Complement Car	Complement Car	Completified Col	Collipiement Cst	Complement C3f	Complement C3f	Complement C3f	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Serum Albumin	Serum Albumin	Serum Albumin	Serum Alburnin						
MΜ	1440	1449	1449	1449	1449	1449	1449	1440	1449	1440	1440	1440	1440	1440	1440	7440	0 0 7 7	1449	1449	1449	1465	1465	1465	1465	1465	1465	1465	1465	1465	1400	1400	1400	1405	1465	1465	1518	1518	1518	1521	1521	1521	1521
Disease	CHE	CHE	SFS	당	HZ)	FS	분	SHE	AHO.	HE.	HE C	H.S.	H H	HZ.	75.	HZ.		ב ב	ב ק	- E- C-	Kenal Fallure	Kenal Failure	Renal Failure	Kenal Failure	Kenai Failure	Kenal Failure	Kenal Failure	Renal failure	Renai fallure	Strate Idilure	Stroke-ICH	Stroke-ICH	Stroke-ICH	Olloke-ICH	Stroke-ICH	Ž	×	Ξ	Renal Failure	Renal Failure	Renal Failure	Renal Failure
Patient History	STAGE 3	STAGE 4	STAGE 3	STAGE 3	STAGE3 - DEAD	STAGE 3	STAGE 3	STAGE 3	STAGE 3	Acute MI - STAGE 3		STAGE 4	STAGE 3	STAGE 3	STAGE 3	STAGE 3	STAGE 3	STAGE 3	STAGE 3								Unstable applies hemodicilistic	Unstable andina homoseliation	Rapid atrial Fib. Drive Hy CAN homodishois	HCI	HTN ICH right thalmic	HTN ICH (cerebellar vermis)	HTN acute CVA (B. subcortical	LTN Dishoto Cont. C. C. D.	nin, Diabetes, acute CVA (R panetal)							
ar Age	29	75	77	65	29	67	79	90	43	45	59	99	51	64	29	9/	51	62	0,	2	67	12	, Q	3 2	3 6	95	99	89	8	4	99	9/	72	67	8	3 6	3	ç	200	اه	> 6	8
Gender		ш	ıL	ட	Σ	Σ	Σ	Σ	Σ	Σ	Σ	ıι	Σ	Σ	Σ	ட	Σ	Σ	Σ	Σ	u	. L	- ≥	Σ	u	. L	. 2	Σ	L	և	Σ	L	Σ	և	. 2	<u>E</u>	_	2	Ę u	L	<u>- </u>	ž
Code #	22703 - MMS	20206 - MM	22103 - GM	21813 - GR	23008 - GFB	23402 - HM	20208 - HIF	22803 - HB	23616 - JGK	20803 - EW	23421 - FB	22813 - CL	23130 - ER	23105 - FC	23116 - FC	20414 - EYG	23130 - ER	23134 - FC	20102 - EAB	SJ CON 01	SJ CON 05	SJ CON 06	STCON 08	SJ CON 07	ST-CON-10	SJ CON 14	SJ CON 04	SJ CON 11	SJ CON 13	CU-12	CU-10	CU-16	CU-37	CU-38	SJ CON 07	S.I.CON 10	HNS-S 122	S LONION ON	SO CON OF	50 NOO 65	SO NOO OS	20 000 00

	REKD(L)	REKD(L)	REKD(L)	REKD(L)	REKD(L)	REKD(L)	PEKY(-)	PEKY(-)	JEKY(-)	3GGVR(G)	SLL(R)	SLL(R)	SLL(R)	SLL(R)	SLL(R)	SLL(R)	SLL(R)	SLL(R)		SLL(R)																				
Sequence	(R)DAHKSEVAHRFKD(L	(R)DAHKSEVAHRFKD(L	(R)DAHKSEVAHRFKD(L	(R)DAHKSEVAHRFKD(L	(R)DAHKSEVAHRFKD(L	(R)DAHKSEVAHRFKD(L	(D)PNHFRPAGLPEKY(-)	(D)PNHFRPAGLPEKY(-	(D)PNHFRPAGLPEKY(-)	(T)ADSGEGDFLAEGGGVR(G	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	A OF (#1//)	(ア)コカイカリ ハー・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・																				
Protein Name	Serum Albumin	Serum Albumin	Serum Albumin	Serum Albumin	Serum Albumin	Serum Albumin	Serum Amyloid A	Serum Amyloid A	Serum Amyloid A	Alpha Fibrinogen	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	300 12000	Complement Co																				
ΜW	1521	1521	1521	1521	1521	1521	1525	1525	1525	1536	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	4500	200
Disease	Renal Failure	Renal Failure	Renal Failure	Renal failure	Renal failure	Renal failure	Mi	Ξ	M	M	M	M	Ξ	M	M	M	Σ	₩	Σ	문	CHF	CHF	托	CHF	봈	문	CH	봀	분	CHF	去!	HZ.	CAF	H	불	CFF	CHF	CAF	חחכ	ב
Patient History				Unstable angina, hemodialysis	Unstable angina, hemosdialysis	Rapid atrial Fib, Prior Hx CAN hemodialysis														STAGE 3	STAGE 3	STAGE 3		STAGE 3	STAGE 3	STAGE3 - DEAD	STAGE 3	STAGE 3	STAGE 3		Acute IVII - STAGE 3	STAGE 3	STAGE 4	STAGE 3	STAGE 3	STAGE 3		STAGE 3	STACE 2	0.100.0
r Age	92	20	92	99	98	80	20			Ī	77	65	20	92	28	52	65			91	65	29	75	77	65	67	67	6/	200	43	Ç	S S	9	21	64	23	9/	51	63	3
Gender	Σ	ш	ட	Σ	Σ	ட	ш				ட	Σ	ц	ட	Σ	Σ	Σ			Σ	щ	ıL	L.	ட	L	≥ :	≥ :	Σ	Σ	2 2	≦ 2	ΣL		≥ :	Σ	Σ	ட	Σ	Σ	
Code #	SJ CON 07	SJ CON 10	SJ CON 14	SJ CON 04	SJ CON 11	SJ CON 13	SJ CON 10	HNS-SJ22	HNS-SJ28	HNS-SJ22	SJ CON 06	SJ CON 07	SJ CON 10	SJ CON 14	SJ CON 17	SJ CON 19	SJ CON 21	HNS-SJ22	HNS-SJ33	23604 - KKB	23707 - KL	22703 - MMS	20206 - MM	22103 - GM	21813 - GR	23008 - GFB	23402 - HM	20208 - HIF	22603 - HB	20803 EM	22424 - EVV	23421 - FB	22813 - CL	23130 - ER	23105 - FC	23116 - FC	20414 - EYG	23130 - ER	23134 - FC	

der /		Patient History		Disease	MW 1616	Protein Name Complement C3f	Sequence
				MI	1616	Complement C3f	
	2			ΞW	1616	Complement C3f	
M 58	3		- !	Ξ	1616	Complement C3f	
M 65			1	2 2	1616	Complement C3f	
				Σ	1616	Complement C3f	
				M	1616	Complement C3f	
				MI	1616	Complement C3f	
			li	ΙΜ	1690	Complement C3f	(S)KITHRIHWESASLL(R)
	2		- 1	Σ	1690	Complement C3f	(S)KITHRIHWESASLL(R)
+			- 1	Σ	1690	Complement C3f	(S)KITHRIHWESASLL(R)
\dashv	2		- 1	M	1690	Complement C3f	(S)KITHRIHWESASLL(R)
58				Ξ	1690	Complement C3f	(S)KITHRIHWESASLL(R)
69 ICH, seco		ICH, secondary to AVM		Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CH ICH	HO.			Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
54 Acute CVA, Basal ganglia	Acute CVA, Basal ganglia	a	0)	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
66 HTN, ICH right thalmic	HTN, ICH right thalmic			Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
50 HTN, acute CVA	HTN, acute CVA			Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
76 HTN, ICH (cerebellar vermis)	HTN, ICH (cerebellar vermis)		ارن	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
/Z HTN, previous CVA, CVA (R MCA) used tPA	HTN, previous CVA, CVA (R MCA) used tPA	-		Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
4/ CVA, transfer to VA	CVA, transfer to VA			Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
M 56 HTN ICH		HOI WILL		Stroke-ICH Stroke ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
72 Prior CVA,	Prior CVA, acute CVA (L M	Prior CVA, acute CVA (L MCA)	1	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASIL(K)
72	HTN, acute CVA (R subcort	HTN, acute CVA (R subcortical		Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
29	-	HTN, Diabetes, acute CVA (R parietal)		Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
64 HTN, Pric	+	HTN, Prior CVA, ICH (R thalamic hemorrhage)	- 1	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
49		HTN, Prior CVA, CVA	- 1	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
43 HTN,		HTN, Prior CVA, ICH	ı	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
61		STAGE 3		CFF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
65		STAGE 3		CHE	1690	Complement C3f	(S)KITHRIHWESASLL(R)
67		STAGE 3		분	1690	Complement C3f	(S)KITHRIHWESASLL(R)
75		STAGE 4		CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
77		STAGE 3		CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
		STAGE 3		CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
67 ST/		STAGE3 - DEAD		CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
29	STAGE	STAGE 3	1 1	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
79		STAGE 3	1	CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)
		STAGE 3	į	문	1690	Complement C3f	(S)KITHRIHWESASLL(R)
M 43 STAGE 3		STAGE 3		CHF	1690	Complement C3f	(S)KITHRIHWESASLL(R)

Sequence	(S)KITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)										
Protein Name	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f											
MΜ	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	
Disease	胀	CHF	분	CHF	당	CHF	분S	HS	CAF	CHF	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	×	Type II Diabetes	Type II Diabetes	Type II Diabetes	M	M	M	M	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	CHF	1.0
Patient History	Acute MI - STAGE 3	STAGE 3	STAGE 4	STAGE 3	NIDDM, CHF, Hypothalemia??	patient died of CA Dec. 22/98	hemodialysis	hemodialysis		NIDDM, HTN, Rio?? Angina		Aphasia, Rt hemiparalysis,					ICH, secondary to AVM	HOI	Acute CVA, Basal ganglia	HTN, ICH right thalmic	HTN, acute CVA	HTN, ICH (cerebellar vermis)	HTN, previous CVA, CVA (R MCA) used tPA	CVA, transfer to VA	HIN, ICH	HTN, ICH	Prior CVA, acute CVA (L MCA)	HTN, acute CVA (R subcortical	HTN, Diabetes, acute CVA (R parietal)	HTN, Prior CVA, ICH (R thalamic hemorrhage)		HTN, Prior CVA, ICH	STAGE 3	C L(<+6						
r Age	45	29	99	51	64	29	92	51	62	70	82	82	29	77	11	80	81	76	65	22	65	28	69	44	25	99	20	76	7.5	47	32	26	72	72	29	64	49	43	91	ü
Gender	Σ	Σ	u.	Σ	Σ	Σ	ட	Σ	Σ	Σ	Σ	Σ	<u>.</u>	<u>.</u>	L.	Σ	≥	Σ	Σ	щ	щ	Σ	۱ ا	щ	ц.	∑ :	اِ	- :	Σ :	Σ :	Σ.	≥ :	∑ :	Σ	щ	Σ	Σ	Σ	Σ	ட
Code #	20803 - EW	23421 - FB	22813 - CL	23130 - ER	23105 - FC	23116 - FC	20414 - EYG	23130 - ER	23134 - FC	20102 - EAB	SJ CON 01	SJ CON 01	SJ CON 05	SJ CON 06	SJ CON 06	SJ CON 09	1WH-002	TWH -009	SJ CON 07	SJ CON 10	SJ CON 14	SJ CON 17	69-00	CU-12	CU-15	CU-10	CU-14	CO-16	CO-18	81-00	27-78 01-88	CO-30	CU-33	CU-37	CU-38	09-NO	99-NO	CU-75	23604 - KKB	23707 - K

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
20206 - MM	ட	75	STAGE 4	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
22103 - GM	U.	77	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
21813 - GR	IJ.	65	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23008 - GFB	Σ	29	STAGE3 - DEAD	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23402 - HM	Σ	29	STAGE 3	CHE	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
20208 - HIF	Σ	79	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
22803 - HB	Σ	8	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23616 - JGK	Σ	43	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
20803 - EW	Σ	45	Acute MI - STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23421 - FB	Σ	29	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
22813 - CL	ш	99	STAGE 4	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23130 - ER	Σ	51	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23105 - FC	Σ	64	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23116 - FC	Σ	29	STAGE 3	CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
20414 - EYG	ц.	9/		CHF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23130 - ER	Σ	21	STAGE 3	CAF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
23134 - FC	Σ	62		SF	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
20102 - EAB	Σ	2	STAGE 3	분	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
TWH-002	Σ	8		Type II Diabetes	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
600- HML	Σ	76	Aphasia, Rt hemiparalysis,	Type II Diabetes	1777	Complement C3f	(S)SKITHRIHWESASLL(R)
TWH-002				Type II Diabetes	1845	Complement C4 fragment	(+)RNGFKSHALQLNNRQIR(-)
600- HML				Type II Diabetes	1845	Complement C4 fragment	(+)RNGFKSHALQLNNRQIR(-)
TWH-024				Type II Diabetes	1845	Complement C4 fragment	(+)RNGFKSHALQLNNRQIR(-)
TWH-039				Type II Diabetes	1845	Complement C4 fragment	(+)RNGFKSHALQLNNRQIR(-)
743-450				Type II Diabetes	1845	Complement C4 fragment	(+)RNGFKSHALQLNNRQIR(-)
184-988				Type II Diabetes	1845	Complement C4 fragment	(+)RNGFKSHALQLNNRQIR(-)
734-989				Type II Diabetes	1845	Complement C4 fragment	(+)RNGFKSHALQLNNRQIR(-)
SJ CON 01	Σ	82		Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
SJ CON 06	J. 1			Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
SJ CON 06	<u> </u>	77		W	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
SO CON 08	Σ:	S :	Hx of prostate CA, hemodialysis	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
IWH-002	Σ	84		Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
1WH -009	Σ	9/	Complete hemianopia, smoker	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
TWH-024	Σ	63	Stroke, PM Hx, NIDDM, incr BP	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
TWH-039	Σ	62		Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
184-988	Σ.	73	MODIN	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
734-989	Σ.	ဌ	MOGIN	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
SJ CON 07	١	දු		≅	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
S2 CON 10	L	30		X	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
00 CON 14	L 2	S		Z	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
1 NOO 00	ž	g		M	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)

Sequence	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLI(R)	(+)SSKITHRIHWESASLL(R)																												
Protein Name	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f							
MW	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865
Disease	M	M	M	MI	M	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	CFF	CH	붓	CAF	CHF	SF	분	CHF	똤	CFF	CFF	CHF	문	CHF						
Patient History	101/100-101					ICH, secondary to AVM	HOI	Acute CVA, Basal ganglia	HTN, ICH right thalmic	HTN, acute CVA	HTN, ICH (cerebellar vermis)	HTN, previous CVA, CVA (R MCA) used tPA	CVA, transfer to VA	HTN, ICH	HTN, ICH	Prior CVA, acute CVA (L MCA)	HTN, acute CVA (R subcortical	HTN, Diabetes, acute CVA (R parietal)	HTN, Prior CVA, ICH (R thalamic hemorrhage)	HTN, Prior CVA, CVA	HTN, Prior CVA, ICH	STAGE 3	STAGE 3	STAGE 3	STAGE 4	STAGE 3	STAGE 3	STAGE3 - DEAD	STAGE 3	STAGE 3	STAGE 3		Acute MI - STAGE 3	STAGE 3	STAGE 4	STAGE 3					
الد	52	65				69	44	54	99	20	76	72	47	22	26	72	72	29	64	49	43	61	65	29	75	77	65	29	29	6/	9	43	45	28	99	51	64	29	9/	21	62
Sender	Σ	Σ				ıı	ıL	Щ	Σ	Σ	ц.	Σ	Σ	Σ	Σ	≥ :	Σ	ш	Σ	Σ	Σ	Σ	١	_	L	L I	ц.	Σ :	Σ:	∑ :	≥ :	≥ :	Σ	Σ	ц	Σ	∑	Σ	ட	Σ	Σ
Code #	SJ CON 19	SJ CON 21	HNS-SJ22	HNS-SJ28	HNS-SJ33	69-NO	CU-12	CU-15	CU-10	CU-14	CU-16	CU-18	CU-19	CU-28	CU-30	CU-33	CU-37	CU-38	09-00	99-00	CU-75	23604 - KKB	23/0/ - KL	22/03 - MMS	20206 - MM	22103 - GM	21813 - GR	23008 - GFB	23402 - HM	20208 - HIF	22803 - HB	23616 - JGK	20803 - EW	23421 - FB	22813 - CL	23130 - ER	23105 - FC	23116 - FC	20414 - EYG	23130 - ER	23134 - FC

Sequence	(+)SSKITHRIHWESASI I (R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASI I (R)	(R)NGFKSHALOLNNROIR(G)	(R)NGFKSHALQLNNRQIR(G)	(R)NGFKSHALQLNNRQIR(G)	(+)SSKITHRIHWESASLL(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASI I R(-)	(+)SSKITHRIHWESASLLR(-)																											
Protein Name	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C4A	Complement C4A	Complement C4A	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f							
MW	1865	1865	1865	1865	1865	1865	1865	1896	1896	1896	1998	1998	1998	1998	1998	1998	1998	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021
Disease	SFF	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	W	MI	MI	Type II Diabetes	Type II Diabetes	MI	Type II Diabetes	W	W	W	W	Ξ			W		문				CHF													
Patient History	STAGE 3			Stroke, PM Hx, NIDDM, incr BP		MIDDM	MIDDM																														STAGE 3	STAGE 3	STAGE 3	STAGE 4	STAGE 3
Age	20			63		73	65	65	28									82	1	77	80	8	9/	63	62	73	65	65	2	S	ဂ္ဂ	25	ည			į	61	65	/9	0 !	\ //
Gender Age	Σ			Σ		Σ	Σ	Σ	Σ									Σ	LIL	u.	≥	Σ	≥ :	Σ.	Σ	≥ :	Σ :	۱ع	L	L 2	2	≦ :	≥				اع	1. [L	-
Code #	20102 - EAB	TWH-002	600- HMI	1WH-024	I WH-039	184-988	734-989	SJ CON 07	SJ CON 17	HNS-SJ22	TWH-002	600- HMI	TWH-024	I WH-039	/43-450	184-988	/34-989	SJ CON 01	SJ CON 06	SJ CON 06	SJ CON 09	TWH-002	600- HM	1 WH-024	1 WH-039	184-988	7.34-989	SJ CON 07	SUCCIN 10	02 CON 4	92 CON 1	81 CON 18	S NO CON Z	HNS-SJ22	HNS-SJZ8	HNS-8J33	23504 - KKB	23/0/ - KL	20206 MMS	20200 - MIM	ZZ103 - GM

Code #	Gender	Age	Pa	Disease	MW	Protein Name	Sequence
21813 - GR	щ	65	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
23008 - GFB	Σ	29	STAGE3 - DEAD	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
23402 - HM	≥	29	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
20208 - HIF	Σ	79	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
22803 - HB	Σ	8	STAGE 3	당	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
23616 - JGK	≥	43	İ	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
20803 - EW	Σ	45	Acute MI - STAGE 3	CAF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
23421 - FB	Σ	29	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
22813 - CL	ட	99	STAGE 4	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
23130 - ER	Σ	51	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
23105 - FC	Σ	95	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
23116 - FC	Σ	29	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
20414 - EYG	ட	9/	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
23130 - ER	Σ	21	STAGE 3	CAF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
23134 - FC	Σ	62	STAGE 3	CHF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
20102 - EAB	Σ	2	STAGE 3	CFF	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
1 WH-002				Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
600- HMI				Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
1 WH-024				Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
WH-039				Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
184-988				Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
734-909	2	3		Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
33707 KIB	∑ [u	10	STAGE 3	당	2056	Complement C3f	SSKITHRIHWESASLLR
22707 - NE	L	000	S I AGE 3	士5	2026	Complement C3f	SSKITHRIHWESASLLR
20206 NAME	L	10	SIAGE 3	ES.	2056	Complement C3f	SSKITHRIHWESASLLR
20200 - MIM	L	0 1	SIAGE 4	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
- CO C C C C C C C C C C C C C C C C C C	LL	: 2	SIAGE 3	CHE	2056	Complement C3f	SSKITHRIHWESASLLR
23008 CEB	L 2	3 2	SIAGE 3	SF.	2056	Complement C3f	SSKITHRIHWESASLLR
23402 - GFB	2	0 2	SIAGES - DEAD	CHF	2056	Complement C3f	SSKITHRIHWESASLLR
20208 LIE	≦ 2	0	SIAGE 3	HS	2056	Complement C3f	SSKITHRIHWESASLLR
11L - 003	≥ 2	2 2	SIAGE 3	분S	2056	Complement C3f	SSKITHRIHWESASLLR
22003 - HB	∑ :	3	STAGE 3	CAF	2056	Complement C3f	SSKITHRIHWESASLLR
23010 - JGK	≥ :	5		당	2056	Complement C3f	SSKITHRIHWESASLLR
20803 - EW	∑ :	5	Acute MI - STAGE 3	분	2056	Complement C3f	SSKITHRIHWESASLLR
23421 - FB	اچ	29	STAGE 3	분	2056	Complement C3f	SSKITHRIHWESASLLR
22813 - CL	L	9	STAGE 4	SF	2056	Complement C3f	SSKITHRIHWESASLLR
23130 - ER	≥ :	51	STAGE 3	CAF	2056	Complement C3f	SSKITHRIHWESASLLR
23105 - FC	∑ :	4 6	STAGE 3	CAF	2056	Complement C3f	SSKITHRIHWESASLLR
23110 - FC	∑ L	26	STAGE 3	분	2056	Complement C3f	SSKITHRIHWESASLLR
30 50	_ 2	2 2	STAGE 3	H	2056	Complement C3f	SSKITHRIHWESASLLR
23130 - ER	M	0	SIAGES	분S	2056	Complement C3f	SSKITHRIHWESASLLR

_	11			_		_	Ţ	_			,	-	_		
Sequence	SSKITHRIHWESASLLR	SSKITHRIHWESASLLR	(A)TVGSLAGQPLQERAQAWGERL(R)	(A)TVGSLAGQPLQERAQAWGERL(R)	(A)TVGSLAGQPLQERAQAWGERL(R)	(R)DAHKSEVAHRFKDLGEENFKALVL(I)	(R)DAHKSEVAHRFKDLGEENFKALVL(I)	(R)DAHKSEVAHRFKDLGEENFKALVL(I)	(R)DAHKSEVAHRFKDLGEENFKALVL(I)	(R)DAHKSEVAHRFKDLGEENFKALVL(I)	(R)DAHKSEVAHRFKDLGEENFKALVLIA(F)	(R)DAHKSEVAHRFKDLGEENFKALVLIA(F)	(R)DAHKSEVAHRFKDLGEENFKALVLIA(F)	(R)DAHKSEVAHRFKDI GEENFKAI VI 1A(F)	(R)DAHKSEVAHRFKDLGEENFKALVLIA(F)
Protein Name	Complement C3f	Complement C3f	Apoliprotein E	Apoliprotein E	Apoliprotein E	Serum Albumin	Serum Albumin	Serum Albumin	Serum Albumin	Serum Albumin					
MW	2056	2056	2267	2267	2267	2753	2753	2753	2753	2753	2937	2937	2937	2937	2937
Disease	CHF	분	Insulin Resistance	Insulin Resistance	Insulin Resistance	Insulin Resistance	Insulin Resistance	Insulin Resistance	Insulin Resistance	Insulin Resistance	Insulin Resistance	Insulin Resistance	Insulin Resistance	Insulin Resistance	Insulin Resistance 2937
Patient History	STAGE 3	STAGE 3	Insulin Resistance	Insulin Resistance	Insulin Resistance	Insulin Resistance	Insulin Resistance	Insulin Resistance	Insulin Resistance	Insulin Resistance	Insulin Resistance	Insulin Resistance	Insulin Resistance	Insulin Resistance	Insulin Resistance
Age	62	20	7	۷	2	۷	ç	خ	خ	ć	٠.	٠.	ć	۲.	ح.
Gender Age	Σ	Σ	Σ	ш	Щ	Σ	Σ	ц	щ	ц.	Σ	Σ	щ	LL.	L
Code #	23134 - FC	20102 - EAB	3111898	112698	5124698	3111898	42698	112698	6101600	5124698	3111898	42698	112698	6101600	5124698